Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Cyclophosphamide vs Rituximab Alone in AAV (ENDURRANCE-1)
NCT03942887Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Leiden University Medical Center. Started May 2019; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT03942887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942887.